XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Details)
$ in Thousands, ₪ in Millions
3 Months Ended 6 Months Ended 9 Months Ended
Oct. 17, 2017
USD ($)
Sep. 18, 2017
USD ($)
Aug. 17, 2017
USD ($)
Aug. 08, 2017
USD ($)
Aug. 08, 2017
ILS (₪)
Sep. 30, 2017
USD ($)
shares
Jun. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
shares
Jun. 30, 2017
USD ($)
Sep. 30, 2017
USD ($)
shares
Sep. 30, 2016
USD ($)
shares
Dec. 31, 2016
USD ($)
Liquidity [Abstract]                        
Accumulated deficit           $ 144,363       $ 144,363   $ 196,321
Shareholders' equity           198,286       198,286   $ 117,928
Proceeds from sale of common shares of subsidiary                   9,968 $ 0  
Grants approved           $ 1,225   $ 1,109   $ 1,236 $ 3,346  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                        
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) | shares           115,298   103,613   111,124 99,073  
Reclassification [Abstract]                        
Gain on sale of assets           $ 0 $ 1,800 $ 0 $ 1,800 $ 1,754 $ 0  
IIA (formerly OCS) grant income (Cell Cure, Israel) [Member]                        
Liquidity [Abstract]                        
Grants approved       $ 2,000                
Grants receivable           1,200       1,200    
IIA (formerly OCS) grant income (Cell Cure, Israel) [Member] | Maximum [Member]                        
Liquidity [Abstract]                        
Grants approved | ₪         ₪ 7.2              
N I H Grant Income [Member] | Maximum [Member]                        
Liquidity [Abstract]                        
Grants approved   $ 1,560                    
Asterias Biotherapeutics and OncoCyte [Member]                        
Liquidity [Abstract]                        
Cash and cash equivalents, available for sale securities, combined value           184,700       184,700    
AgeX [Member]                        
Liquidity [Abstract]                        
Proceeds from sale of common shares of subsidiary     $ 10,000                  
Parent [Member]                        
Liquidity [Abstract]                        
Accumulated deficit           (144,400)       (144,400)    
Working capital           17,200       17,200    
Shareholders' equity           209,000       209,000    
Cash, cash equivalents and available for sale securities           $ 18,200       $ 18,200    
Parent [Member] | Subsequent Event [Member]                        
Liquidity [Abstract]                        
Net proceeds from underwritten public offering $ 26,700                      
Treasury Stock [Member]                        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                        
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) | shares               620,000   109,000 3,400,000  
Restricted Stock Units (RSUs) [Member]                        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                        
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) | shares           10,000   282,000   26,000 154,000  
Stock Options [Member]                        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                        
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) | shares           10,000   282,000   26,000 154,000  
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares) | shares           7,915,000   5,652,000   7,871,000 5,652,000  
Warrants [Member]                        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                        
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares) | shares           9,395,000   9,395,000   9,395,000 9,395,000